quinazolines has been researched along with Malignant Melanoma in 71 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.82) | 18.2507 |
| 2000's | 19 (26.76) | 29.6817 |
| 2010's | 47 (66.20) | 24.3611 |
| 2020's | 3 (4.23) | 2.80 |
| Authors | Studies |
|---|---|
| Fenical, W; Hillman, PF; Kim, MJ; Lee, SE; Lim, KM; Nam, SJ; Oh, DC | 1 |
| Bobera, J; Dupuy, AJ; Feddersen, CR; Jennings, BM; Mullen, SA; Riordan, JD; Schillo, JL; Stipp, CS; Varzavand, A; Vaughn, HR; Voigt, AP; Wadsworth, LS; Zhu, EY | 1 |
| Chen, X; Guo, J; Liang, L; Liu, H; Liu, J; Liu, N; Peng, C; Qi, M; Su, J; Zhang, J; Zhao, S | 1 |
| Chen, CM; Cheng, CY; Lin, KY; Lu, CY; Wu, YH | 1 |
| Lim, SY; Menzies, AM; Rizos, H | 1 |
| Andersson, C; Blom, K; Edqvist, PH; Fryknäs, M; Gustafsson, MG; Jarvius, M; Larsson, R; Nazir, M; Nyberg, F; Nygren, P; Senkowski, W | 1 |
| Hou, W; Wan, X; Zhang, L; Zhu, Y | 1 |
| Chen, YX; Dong, J; Guo, YW; Lan, WJ; Li, HJ; Ma, WZ; Shaker, S; Sun, TT; Wang, LY; Wu, DL; Yang, DP; Zhu, LP | 1 |
| Abel, EV; Amaravadi, RK; Aplin, AE; Basile, KJ; Ertel, A; Fortina, P; Karakousis, GC; Kugel, CH; Le, K; Lee, JB; Schuchter, LM; Witkiewicz, AK; Xu, W; Xu, X | 1 |
| Blanchet, B; Boudou-Rouquette, P; Dupin, N; Goldwasser, F; Mortier, L; Sakji, L; Thomas-Schoemann, A; Vidal, M; Zhen, Y | 1 |
| Amaro, A; Angelini, G; Esposito, AI; Lanza, F; Mirisola, V; Mosci, C; Musso, A; Nasciuti, F; Perri, P; Pfeffer, U; Poggi, A; Puzone, R; Salvi, S; Tosetti, F; Truini, M | 1 |
| Liu, YP; Luo, YH; Song, JG; Sun, P; Xu, HM; Zhang, L; Zhang, XJ | 1 |
| Bastian, BC; Chen, X; Emery, C; Jager, MJ; Porter, D; Tan, L; Wu, Q | 1 |
| Ambrosini, G; de Stanchina, E; Musi, E; Schwartz, GK | 1 |
| Emmert, S; Liu, N; Pletz, N; Schneider, P; Schön, M; Schön, MP; Seitz, CS; Zachmann, K; Ziegelbauer, K | 1 |
| Azzariti, A; Cocco, T; Ferretta, A; Guida, G; Guida, M; Guida, S; Iacobazzi, RM; Maida, I; Porcelli, L; Quatrale, AE; Sidella, L; Stolfa, DA; Strippoli, S; Tommasi, S | 1 |
| Anto, RJ; Antony, J; Chandran, H; Joseph, SM; Katiki, MR; Murty, MS; Nath, LR; Nishanth, KS; Panakkal, EJ; Paul, A; Rajan, E; Ran, S; Saikia, M; Sankar, S; Shabna, A; Sridivya, I; Sriramya, I; Vinod, V | 1 |
| Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT | 1 |
| Adamus, G; Amundson, D; Boon, CJ; Haanen, JB; Jager, MJ; Kapiteijn, EH; Keunen, JE; Luyten, GP; Marinkovic, M; van Dijk, EH; van Herpen, CM | 1 |
| Uhara, H | 1 |
| Amzallag, A; Baniya, S; Benes, CH; Cooper, ZA; Fisher, DE; Flaherty, KT; Frederick, DT; Friedman, AA; Haber, DA; Hargreaves, L; Igras, V; Lawrence, DP; Piris, A; Pruteanu-Malinici, I; Ramaswamy, S; Wargo, JA | 1 |
| Bekiranov, S; Capaldo, B; Conaway, MR; Gioeli, D; Mackey, AJ; Petricoin, EF; Roller, DG; Weber, MJ | 1 |
| Gajewski, T; Hui, J; McWhirter, E; Oza, A; Pond, G; Quirt, I; Wang, L | 1 |
| Czyz, M; Gajos-Michniewicz, A | 1 |
| Carita, G; Cassoux, N; Dahmani, A; De Koning, L; Decaudin, D; Emery, C; Frisch-Dit-Leitz, E; Halilovic, E; Jeay, S; Laurent, C; Némati, F; Piperno-Neumann, S; Raymondie, C; Roman-Roman, S; Schoumacher, M; Wylie, A | 1 |
| Collins, L; Corner, C; Goff, M; Gupta, A; Kelly, C; Lester, J; Love, S; Marshall, E; Middleton, MR; Nobes, J; Roberts, C; Salisbury, A; Tysoe, F; Wise, A; Wolstenholme, V; Woodward, M | 1 |
| Aurisicchio, L; Bedogni, B; Cappelletti, M; Lu, J; Pavoni, E; Roscilli, G; Thakur, V; White, WL | 1 |
| Abdiu, A; Djerf, EA; Hallbeck, AL; Thunell, LK; Trinks, C; Walz, TM | 1 |
| Elenius, K; Grenman, R; Iivanainen, E; Kulmala, J; Lauttia, S; Salven, P; Tvorogov, D; Zhang, N | 1 |
| Agrawal, NS; Cronin, JC; Cruz, P; Lin, JC; Prickett, TD; Rosenberg, SA; Samuels, Y; Wei, X; Wunderlich, JR; Yates, KE | 1 |
| Alvino, E; Bonmassar, E; Brasca, MG; Caporali, S; Castiglia, D; Ciomei, M; Covaciu, C; D'Atri, S; Garbin, A; Levati, L; Starace, G | 1 |
| Ardinghi, C; Bani, MR; Bernasconi, S; Carraro, F; Ghilardi, C; Giavazzi, R; Naldini, A; Oliva, P; Silini, A | 1 |
| Deng, WG; Ekmekcioglu, S; Grimm, EA; Kwon, J; Poindexter, NJ | 1 |
| Cho, SJ; Hah, JM; Kim, DJ; Kim, H; Lee, J; Lee, SH; Nam, BS; Oh, CH; Sim, TB; Tae, J; Yoo, KH | 1 |
| Katsifis, A; Lin, HQ; Meriaty, H | 2 |
| Chattopadhyay, B; Chattopadhyay, P; Dhara, K; Helliwell, M; Khuda-Bukhsh, AR; Mandal, SK; Mukherjee, M; Saha, UC; Sarkar, S | 1 |
| Ashton, S; Barry, ST; Blakey, D; Lewis, CE; Murdoch, C; Tazzyman, S; Wood, P | 1 |
| Bar-Eli, M; Bassett, RL; Bedikian, AY; Bronstein, Y; Dobroff, A; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Patel, SP; Prieto, VG; Vardeleon, AG; Zigler, M | 1 |
| Botti, G; D'Antonio, A; De Luca, A; Hendrix, MJ; Hsu, MY; Lamura, L; Margaryan, N; Mari, E; Normanno, N; Pirozzi, G; Roma, C; Salomon, DS; Strizzi, L | 1 |
| Goozner, M | 1 |
| Bardelli, A; Beijersbergen, RL; Bernards, R; Di Nicolantonio, F; Huang, S; Prahallad, A; Salazar, R; Sun, C; Zecchin, D | 1 |
| Arozarena, I; Ehrhardt, M; Ferguson, J; Wellbrock, C | 1 |
| Juergens, R; Levine, MN | 1 |
| Lo, RS | 1 |
| Fletcher, JA; Hodi, FS; Li, J; Wu, X; Zhu, M | 1 |
| Alvino, E; Bonmassar, E; Brasca, MG; Caporali, S; Ciomei, M; D'Atri, S; Del Bufalo, D; Desideri, M; Esposito, AI; Levati, L; Pfeffer, U | 1 |
| Burton, L; Chan, E; Fridlyand, J; Koeppen, H; Li, J; Lin, E; Merchant, M; Moffat, J; Neve, R; Peng, J; Penuel, E; Ribas, A; Settleman, J; Sosman, J; Sutherlin, DP; Wang, Y; Wilson, TR; Yan, Y | 1 |
| Baldi, A; Citro, G; Fanciulli, M; Spugnini, EP | 1 |
| Bahleda, R; Blay, JY; Dieras, V; LoRusso, P; Macaulay, VM; Mery-Mignard, D; Middleton, MR; Protheroe, AS; Sessa, C; Soria, JC; Tolcher, A | 1 |
| Clark, JI; Gajewski, TF; Gangadhar, TC; Karrison, T | 1 |
| Printz, C | 1 |
| Aquila, B; Augustin, M; Chen, H; Cheung, T; Cook, D; Drew, L; Fauber, BP; Glossop, S; Grondine, M; Hennessy, E; Johannes, J; Lee, S; Lyne, P; Mörtl, M; Omer, C; Palakurthi, S; Pontz, T; Read, J; Sha, L; Shen, M; Steinbacher, S; Vasbinder, MM; Wang, H; Wu, A; Ye, M | 1 |
| Fei, XF; Ikejima, T; Li, TJ; Minami, M; Tashiro, S; Wang, BX; Xing, DJ | 1 |
| Ikejima, T; Onodera, S; Tashiro, S; Wu, LJ; Zhang, Y | 2 |
| Ikejima, T; Onodera, S; Tashiro, S; Wu, LJ; Zhang, QH; Zhang, Y | 1 |
| de Waal, R; Heerschap, A; Küsters, B; Leenders, WP; Maass, C; Ruiter, D; Ryan, A; Verrijp, K; Wesseling, P | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Ikejima, T; Onodera, S; Tashiro, S; Wang, C; Wang, MW | 3 |
| Derby, S; Di, W; Jiang, Q; Qiu, L; Schefeller, E; Wan, Y; Wanebo, H; Wang, Q; Yan, B | 1 |
| de Waal, RM; Kats, G; Küsters, B; Leenders, WP; Roodink, I; Ruiter, DJ; Verrijp, K; Wesseling, P | 1 |
| Koldenhof, JJ; Sigurdsson, V; Tjin-A-ton, ML; van Montfrans, C; Voest, EE; Witteveen, PO | 1 |
| Ikejima, T; Onodera, S; Tashino, S; Wu, LJ; Yang, J | 1 |
| Bélanger, K; Eisenhauer, EA; Lee, CW; Petrella, TM; Rao, SC; Savage, KJ; Seymour, L; Synold, TW; Tozer, RG; Wainman, N; Wood, L | 1 |
| Ikejima, T; Onodera, S; Tashiro, S; Wu, LJ; Yang, J | 1 |
| Cipák, L; Jantová, S; Kubíková, J; Maliar, T; Mikulásová, M; Rauko, P; Spirková, K; Stankovský, S; Urbancíková, M | 1 |
| Akman, S; Carr, B; Doroshow, J; Goldberg, D; Grove, W; Leong, L; Margolin, K; Odujinrin, O | 1 |
| Bodurtha, AJ; Eisenhauer, EA; Iscoe, NA | 1 |
4 review(s) available for quinazolines and Malignant Melanoma
| Article | Year |
|---|---|
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; CTLA-4 Antigen; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunotherapy; Indoles; Ipilimumab; MAP Kinase Kinase 1; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2017 |
[Molecular target therapies for skin cancers].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; CTLA-4 Antigen; Enzyme Inhibitors; Gefitinib; Humans; MAP Kinase Kinase Kinases; Melanoma; Molecular Targeted Therapy; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf; Quinazolines; Skin Neoplasms | 2015 |
Modulation of WNT/β-catenin pathway in melanoma by biologically active components derived from plants.
Topics: Animals; Clinical Trials as Topic; Flavonoids; Flavonols; Humans; Melanoma; Pentacyclic Triterpenes; Phytochemicals; Quinazolines; Silymarin; Wnt Signaling Pathway | 2016 |
Preclinical models in electrochemotherapy: the role of veterinary patients.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cat Diseases; Cats; Cisplatin; Dog Diseases; Dogs; Drug Evaluation, Preclinical; Electrochemotherapy; Epirubicin; Head and Neck Neoplasms; Melanoma; Mitoxantrone; Neoplasms; Quinazolines; Sarcoma; Thiophenes | 2012 |
7 trial(s) available for quinazolines and Malignant Melanoma
| Article | Year |
|---|---|
Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.
Topics: Adult; Aged; Autoantibodies; Benzimidazoles; Central Serous Chorioretinopathy; Cross-Sectional Studies; Drug Combinations; Electrooculography; Electroretinography; Eye Proteins; Female; Fluorescein Angiography; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Prospective Studies; Protein Kinase C; Pyrroles; Quinazolines; Skin Neoplasms; Subretinal Fluid; Tomography, Optical Coherence; Uveal Neoplasms; Visual Acuity | 2015 |
A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Piperidines; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy | 2016 |
A phase II study of gefitinib in patients with metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Choroid Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Texas; Time Factors; Treatment Outcome; Young Adult | 2011 |
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Melanoma; Middle Aged; Quinazolines; Receptor, IGF Type 1; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2013 |
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzodioxoles; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; T-Lymphocytes; Treatment Outcome | 2013 |
A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Drug Delivery Systems; Eye Neoplasms; Female; Humans; Kinesins; Male; Melanoma; Middle Aged; Mucous Membrane; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Skin Neoplasms; Treatment Outcome | 2008 |
60 other study(ies) available for quinazolines and Malignant Melanoma
| Article | Year |
|---|---|
Deoxyvasicinone with Anti-Melanogenic Activity from Marine-Derived
Topics: Animals; Cell Line, Tumor; Down-Regulation; Humans; Melanins; Melanocytes; Melanoma; Melanoma, Experimental; Mice; Quinazolines; Skin; Streptomyces | 2022 |
Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma.
Topics: Antineoplastic Agents; Benzodioxoles; Drug Resistance, Neoplasm; Guanine Nucleotide Exchange Factors; Humans; Melanoma; Melanoma, Cutaneous Malignant; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-vav; Quinazolines; Signal Transduction; Skin Neoplasms; src-Family Kinases; Vemurafenib | 2019 |
Potent USP10/13 antagonist spautin-1 suppresses melanoma growth via ROS-mediated DNA damage and exhibits synergy with cisplatin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylamines; Cell Line, Tumor; Cisplatin; DNA Damage; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Melanoma, Cutaneous Malignant; Mice; Quinazolines; Reactive Oxygen Species; Skin Neoplasms; Ubiquitin Thiolesterase; Ubiquitin-Specific Proteases; Xenograft Model Antitumor Assays | 2020 |
Regulation of miR-21 expression in human melanoma via UV-ray-induced melanin pigmentation.
Topics: alpha-MSH; Animals; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Gefitinib; Humans; Melanins; Melanoma; Melanoma, Experimental; Mice; MicroRNAs; Phosphorylation; Pigmentation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Skin Neoplasms; Ultraviolet Rays | 2017 |
Targeting tumor cells based on Phosphodiesterase 3A expression.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carrier Proteins; Cell Line, Tumor; Colonic Neoplasms; Cyclic Nucleotide Phosphodiesterases, Type 3; Female; Gastrointestinal Stromal Tumors; Gene Expression; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Organ Specificity; Organoplatinum Compounds; Oxaliplatin; Phosphodiesterase Inhibitors; Pyridazines; Quinazolines; RNA, Messenger; Skin Neoplasms | 2017 |
Gefitinib inhibits malignant melanoma cells through the VEGF/AKT signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gefitinib; Humans; Melanoma; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2018 |
Reactive oxygen species altering the metabolite profile of the marine-derived fungus
Topics: Animals; Antineoplastic Agents; Aspergillus; Culture Media; Diketopiperazines; Drug Screening Assays, Antitumor; Ergosterol; Humans; Hydrogen Peroxide; Indoles; Male; Melanoma; Mice; Molecular Structure; Prostatic Neoplasms; Quinazolines; Reactive Oxygen Species; Secondary Metabolism | 2021 |
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.
Topics: Cell Survival; Enzyme Inhibitors; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Indoles; Lapatinib; MAP Kinase Kinase Kinases; Melanoma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Quinazolines; raf Kinases; Receptor, ErbB-3; Signal Transduction; Skin Neoplasms; Sulfonamides; Transcription, Genetic | 2013 |
An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Drug Monitoring; Erlotinib Hydrochloride; Humans; Indoles; Liquid-Liquid Extraction; Melanoma; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Vemurafenib | 2013 |
Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.
Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Cell Line, Tumor; Cell Proliferation; Cetuximab; ErbB Receptors; Gefitinib; Humans; Melanoma; Quinazolines; Signal Transduction; Transcriptome; Uveal Neoplasms | 2013 |
[Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Humans; Melanoma; Morpholines; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tyrphostins | 2013 |
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; GTP-Binding Protein alpha Subunits; GTP-Binding Protein alpha Subunits, Gq-G11; Humans; Inhibitory Concentration 50; MAP Kinase Kinase Kinases; Melanoma; Mice; Mice, Inbred C57BL; Mice, Nude; Mutation, Missense; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Signal Transduction; Tumor Burden; Uveal Neoplasms; Xenograft Model Antitumor Assays | 2014 |
The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gene Silencing; GTP-Binding Protein alpha Subunits; GTP-Binding Protein alpha Subunits, Gq-G11; Humans; Melanoma; Mice; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase C; Pyrroles; Quinazolines; RNA Interference; Signal Transduction; Thiazoles; Tumor Burden; Uveal Neoplasms; Xenograft Model Antitumor Assays | 2014 |
The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Enzyme Inhibitors; Humans; In Vitro Techniques; Melanoma; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Skin Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.
Topics: Albumins; Apoptosis; Aurora Kinase B; Cell Line, Tumor; Cell Movement; Cell Nucleus Shape; Cell Proliferation; Cell Shape; Cell Survival; Drug Resistance, Neoplasm; Extracellular Space; Humans; Lactic Acid; Melanoma; Mitosis; Necrosis; Neoplasm Metastasis; Organophosphates; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines | 2015 |
DW-F5: A novel formulation against malignant melanoma from Wrightia tinctoria.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apocynaceae; Apoptosis; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Disease Models, Animal; Humans; Melanoma; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neovascularization, Pathologic; Plant Extracts; Plant Leaves; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays | 2015 |
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; High-Throughput Screening Assays; Humans; Indoles; Melanoma; Mice; Molecular Targeted Therapy; Proto-Oncogene Proteins B-raf; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Indoles; Lapatinib; MAP Kinase Signaling System; Melanoma; Mice; Mice, Nude; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Sulfonamides | 2016 |
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Enzyme Inhibitors; Everolimus; Humans; Isoquinolines; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mice; Piperazines; Protein Kinase C; Proto-Oncogene Proteins c-mdm2; Pyrroles; Quinazolines; Tumor Suppressor Protein p53; Uveal Neoplasms; Xenograft Model Antitumor Assays | 2016 |
The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Humans; Lapatinib; Male; Melanoma; Mice; Mice, SCID; New Zealand; Polysaccharides; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; RNA, Small Interfering; Transcription Factor RelA; Undaria | 2017 |
ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Melanoma; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Skin Neoplasms; STAT3 Transcription Factor | 2009 |
The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.
Topics: Animals; Antigens; Antineoplastic Agents; Blood Vessels; Bone Marrow Cells; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Endothelium, Vascular; ErbB Receptors; Gefitinib; Humans; Image Processing, Computer-Assisted; Melanoma; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Pericytes; Protein Kinase Inhibitors; Proteoglycans; Quinazolines; Skin Neoplasms | 2009 |
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; ErbB Receptors; Humans; Lapatinib; Melanoma; Mice; Mutation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-4; RNA Interference; Skin Neoplasms | 2009 |
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Coloring Agents; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Dacarbazine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Genes, p53; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Pyrazoles; Quinazolines; Temozolomide; Tetrazolium Salts; Thiazoles | 2010 |
Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype.
Topics: Animals; Cell Line, Tumor; Cell Movement; Disease Progression; Humans; Melanoma; Mice; Mice, SCID; Neoplasm Metastasis; Pyrroles; Quinazolines; Receptor, PAR-1; Skin Neoplasms | 2010 |
IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways.
Topics: Apoptosis; Apoptotic Protease-Activating Factor 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Humans; Interleukins; Melanoma; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Signal Transduction | 2011 |
Synthesis of aminoquinazoline derivatives and their antiproliferative activities against melanoma cell line.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromones; Humans; Melanoma; Quinazolines; Structure-Activity Relationship | 2010 |
Tumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expression.
Topics: Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Melanoma; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
A highly selective fluorescent chemosensor for zinc ion and imaging application in living cells.
Topics: Benzimidazoles; Buffers; Cations, Divalent; Cell Line, Tumor; Cresols; Crystallography, X-Ray; Fluorescent Dyes; HT29 Cells; Humans; Hydrogen-Ion Concentration; Melanoma; Quinazolines; Spectrometry, Fluorescence; Zinc | 2011 |
Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.
Topics: Adenocarcinoma; Animals; Blotting, Western; Cell Proliferation; Chemotaxis; Culture Media, Conditioned; Enzyme-Linked Immunosorbent Assay; Humans; Immunoenzyme Techniques; In Vitro Techniques; Lung Neoplasms; Melanoma; Mice; Mice, Inbred BALB C; Mice, SCID; Neutrophil Infiltration; Quinazolines; Receptors, Interleukin-8B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spheroids, Cellular; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Expression and functional role of CRIPTO-1 in cutaneous melanoma.
Topics: Activin Receptors, Type I; Benzamides; Benzodioxoles; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; CSK Tyrosine-Protein Kinase; Dioxoles; Flow Cytometry; GPI-Linked Proteins; Humans; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Melanoma; Neoplasm Invasiveness; Neoplasm Proteins; Protein-Tyrosine Kinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Skin Neoplasms; Smad Proteins; src-Family Kinases; Tumor Cells, Cultured | 2011 |
Prediction of synergistic antitumour effect of gefitinib and radiation in vitro.
Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Humans; In Vitro Techniques; Melanoma; Phosphorylation; Quinazolines; Radiation, Ionizing; Skin Neoplasms | 2011 |
Drug approvals 2011: focus on companion diagnostics.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib | 2012 |
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Feedback, Physiological; Female; Gefitinib; HEK293 Cells; Humans; Indoles; Melanoma; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; RNA Interference; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.
Topics: Benzimidazoles; Benzodioxoles; Cell Adhesion; Cell Division; Collagen; Humans; Integrin beta1; MAP Kinase Kinase Kinases; Melanoma; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases | 2013 |
Method to our madness or madness in our methods? Pitfalls in trial methodology.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Paclitaxel; Quinazolines; Smoking; Solvents | 2012 |
Receptor tyrosine kinases in cancer escape from BRAF inhibitors.
Topics: Animals; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Melanoma; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor Protein-Tyrosine Kinases; Sulfonamides; Transplantation, Heterologous; Vemurafenib | 2012 |
Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; G1 Phase Cell Cycle Checkpoints; Gene Expression; GTP-Binding Protein alpha Subunits; GTP-Binding Protein alpha Subunits, Gq-G11; Humans; Isoenzymes; MAP Kinase Signaling System; Melanoma; NF-kappa B; Phosphorylation; Protein Kinase C; Protein Processing, Post-Translational; Pyrroles; Quinazolines; Uveal Neoplasms | 2012 |
Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.
Topics: Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinases; Down-Regulation; Gene Regulatory Networks; Humans; Melanoma; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogenes; Pyrazoles; Quinazolines; RNA, Small Interfering; Securin | 2012 |
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Hepatocyte Growth Factor; Humans; Indoles; Lapatinib; Ligands; Melanoma; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Sulfonamides; Vemurafenib | 2012 |
Strides in personalized medicine.
Topics: Afatinib; Gastrointestinal Stromal Tumors; Humans; Lung Neoplasms; Melanoma; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins B-raf; Pyridines; Quinazolines | 2012 |
Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.
Topics: Animals; Humans; Male; Melanoma; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Rats; Structure-Activity Relationship | 2013 |
Evodiamine, a constituent of Evodiae Fructus, induces anti-proliferating effects in tumor cells.
Topics: Alkaloids; Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Division; Cysteine Proteinase Inhibitors; Dactinomycin; DNA Fragmentation; Drug Screening Assays, Antitumor; Enzyme Activation; Evodia; Fibrosarcoma; Fluorouracil; Furans; Gene Expression Regulation, Neoplastic; Genes, bcl-2; HeLa Cells; Hepatocytes; Heterocyclic Compounds, 4 or More Rings; Humans; Indole Alkaloids; Leukemia, Monocytic, Acute; Leukocytes, Mononuclear; Melanoma; Mice; Mitochondria; Molecular Structure; Neoplasm Proteins; Oligopeptides; Plant Extracts; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Rats; Rats, Inbred BUF; Sarcoma 180; Tumor Cells, Cultured | 2003 |
Evodiamine induces tumor cell death through different pathways: apoptosis and necrosis.
Topics: Apoptosis; Caspase 3; Caspase 8; Caspases; Cell Cycle; DNA Fragmentation; Dose-Response Relationship, Drug; Evodia; HeLa Cells; Humans; Melanoma; Mitogen-Activated Protein Kinases; Necrosis; p38 Mitogen-Activated Protein Kinases; Plant Extracts; Plants, Medicinal; Quinazolines; Time Factors | 2004 |
[Evodiamine induces A375-S2 cell death through two different pathways].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspase Inhibitors; Caspases; Cell Cycle; Cell Division; DNA Fragmentation; Dose-Response Relationship, Drug; Evodia; Humans; Melanoma; Plant Extracts; Quinazolines; Time Factors; Tumor Cells, Cultured | 2003 |
Atypical apoptosis in L929 cells induced by evodiamine isolated from Evodia rutaecarpa.
Topics: Adenocarcinoma; Animals; Apoptosis; Breast Neoplasms; Cell Survival; Evodia; Female; Fibrosarcoma; Fruit; Humans; Leukemia, Monocytic, Acute; Leukocytes, Mononuclear; Melanoma; Mice; Plant Extracts; Quinazolines; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2004 |
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.
Topics: Angiogenesis Inhibitors; Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Melanoma; Mice; Mice, Inbred BALB C; Necrosis; Neoplasm Metastasis; Neovascularization, Pathologic; Oligonucleotides, Antisense; Phenotype; Piperidines; Placebos; Quinazolines; RNA; Transfection; Treatment Outcome; Vascular Endothelial Growth Factor A | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Roles of SIRT1 and phosphoinositide 3-OH kinase/protein kinase C pathways in evodiamine-induced human melanoma A375-S2 cell death.
Topics: Androstadienes; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Enzyme Inhibitors; Evodia; Gene Expression; Genes, p53; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; MAP Kinase Signaling System; Melanoma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phytotherapy; Plant Extracts; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Signal Transduction; Sirtuin 1; Sirtuins; Staurosporine; Wortmannin | 2005 |
Evodiamine induced human melanoma A375-S2 cell death partially through interleukin 1 mediated pathway.
Topics: Cell Death; Cell Line, Tumor; DNA Damage; Humans; Interleukin-1; Melanoma; Plant Extracts; Quinazolines; Signal Transduction | 2005 |
Transient activation of EGFR/AKT cell survival pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid.
Topics: Animals; Antineoplastic Agents, Phytogenic; Betulinic Acid; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Survival; Cells, Cultured; Drug Resistance, Neoplasm; Drug Synergism; Embryo, Mammalian; Epidermal Growth Factor; ErbB Receptors; Fibroblasts; Humans; Inhibitor of Apoptosis Proteins; Keratinocytes; Melanoma; Mice; Mice, Knockout; Microtubule-Associated Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Pentacyclic Triterpenes; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Survivin; Time Factors; Triterpenes | 2005 |
[Effect of protein kinase C on human melanoma A375-S2 cell death induced by evodiamine].
Topics: Apoptosis; Cell Line, Tumor; Evodia; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Humans; Melanoma; Plant Extracts; Plants, Medicinal; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Staurosporine | 2005 |
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Piperidines; Pulmonary Embolism; Quinazolines; Skin Neoplasms; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2007 |
[Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors].
Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma; Cetuximab; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2007 |
Critical roles of reactive oxygen species in mitochondrial permeability transition in mediating evodiamine-induced human melanoma A375-S2 cell apoptosis.
Topics: Acridine Orange; Apoptosis; Caspases; Cell Death; Cell Line, Tumor; Cell Nucleus; Cytosol; Humans; Melanoma; Membrane Potentials; Mitochondria; Models, Chemical; Permeability; Plant Extracts; Quinazolines; Reactive Oxygen Species | 2007 |
Nitric oxide activated by p38 and NF-kappaB facilitates apoptosis and cell cycle arrest under oxidative stress in evodiamine-treated human melanoma A375-S2 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Enzyme Activation; Feedback, Physiological; Humans; Imidazoles; Melanoma; Membrane Potential, Mitochondrial; NF-kappa B; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type II; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Plant Extracts; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; Quinazolines; Reactive Oxygen Species; Signal Transduction; Thiocarbamates; Time Factors; Tumor Suppressor Protein p53 | 2008 |
Biological activity of some 4-anilinoquinazolines: cytotoxic, genotoxic and antiprotease effects, induction of necrosis and changes of actin cytoskeleton.
Topics: Animals; CHO Cells; Cricetinae; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Leukemia; Melanoma; Mice; Mutagenicity Tests; Necrosis; Protease Inhibitors; Quinazolines; Skin Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2001 |
Treatment of metastatic malignant melanoma with trimetrexate: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Folic Acid Antagonists; Humans; Male; Melanoma; Middle Aged; Quinazolines; Remission Induction; Trimetrexate | 1990 |
Phase II study of trimetrexate in malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study.
Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Folic Acid Antagonists; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Quinazolines; Trimetrexate | 1990 |